UK preventive inhaler market is anticipated to grow at a substantial growth of around 1.5% during the forecast period. Preventive inhalers are most probably the most important asthma medication as they treat the inflammation inside the airways and decrease the possibility of an asthma exacerbation. As the prevalence of asthma and other diseases increases across UK, the demand for preventive inhalers is also expected to increase for treatment purposes. As per International Monetary Fund GDP of the country was $2.9 trillion in 2017. UK comprises of England, Scotland, Wales and Northern Ireland. Total population of the country in 2017 was 65 million, out of which about 18% are of geriatric population. Mortalities related to asthma and COPD are high in UK and due to these a significant investment by government and people can be forecast in the near future.
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/uk-preventive-inhaler-market
The UK preventive inhaler market is segmented on the basis of device type, application, and end-user. On the basis of device type, the market is sub-segmented into metered dosed inhaler and dry powdered inhaler. The dry powder inhaler is estimated to have largest market share in the UK preventive inhaler market due to providing easy inhalation solution. Whereas, the market for metered dose inhaler is estimated to be the fastest growing at a CAGR during the forecast period owing to innovations and collaborations by the companies for the development of metered dosed inhaler. Moreover, on the basis of application, the market has been classified into asthma and COPD diseases. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed.
Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/uk-preventive-inhaler-market
Furthermore, the market is characterized by the presence of several manufacturers that are developing and providing preventive inhalers to cater to a wide range of customers within the region and across the globe. The major players of the UK preventive inhaler market include Boehringer Ingelheim International GmbH, AstraZeneca PLC, GlaxoSmithKline PLC, Novartis AG, Teva Pharmaceuticals Industries Ltd., Koninklijke Philips N.V., and Bespak. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players.
Market Segmentation
UK Preventive Inhaler Market by Device Type
- Metered Dose Inhaler
- Dry Powder Inhaler
UK Preventive Inhaler Market by Application
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
UK Preventive Inhaler Market by End-User
- Homecare
- Hospitals and Clinics
Company Profiles
- 3M Co.
- Acorda Therapeutics, Inc.
- Adamis Pharmaceuticals Corp.
- Adherium Ltd.
- AstraZeneca PLC
- Bespak
- Boehringer Ingelheim International GmbH
- Chiesi Farmaceutici S.P.A.
- GF Health
- GlaxoSmithKline PLC
- H&T Presspart Manufacturing Ltd.
- Koninklijke Philips N.V.
- Novartis AG
- Omron Healthcare Inc.
- ResMed Corp.
- Pulmatrix Inc.
- Savara, Inc.
- Teicos Pharma Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Vitalograph Ltd.
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
